Adjuvant mitoxantrone + prednisone + ADT in treatment of high-risk prostate cancer

About 25 years ago the addition of the combination of mitoxantrone + prednisone to androgen deprivation therapy (ADT) was the first form of chemotherapy ever approved for the treatment of metastatic, castration-resistant prostate cancer. … READ MORE …

Escalated radiation dose doesn’t improve 8-year overall survival in intermediate-risk men (but does it matter?)

Last week, we saw that escalated dose did not improve 10-year overall survival in high-risk men (see this link). The latest published findings of the randomized clinical trial (RTOG 0126) prove that 8-year overall survival was not improved in intermediate-risk men who received a higher radiation dose. … READ MORE …

Initial local treatment and long-term survival of men with advanced prostate cancer

We have previously had no really accurate data on a very important question: Does local treatment of men initially diagnosed with advanced prostate cancer impact their long-term survival and mortality rates? … READ MORE …

Low PSA levels on ADT do correlate to longer survival times

For many years now, people have asked whether specific PSA levels after initiation of androgen deprivation therapy (ADT, also known as “hormone therapy”)  have significant predictive impact on long-term survival. … READ MORE …

Men initially diagnosed with de novo metastatic prostate cancer are living longer

A newly published study entitled “Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study” is important … but needs to be interpreted with a significant degree of caution. … READ MORE …

A Phase III clinical trial of high-intensity exercise in the management of advanced prostate cancer

According to a news release just issued by Queen’s University, Belfast, a group of  150 researchers around the world is coming together to expand enrollment and access to the Australian INTERVAL trial into a global trial to test whether serious exercise should be prescribed as part of the treatment for men with advanced prostate cancer. … READ MORE …

Why did biochemical control not translate into a survival increase after brachy boost therapy?

The first randomized clinical trial to prove that brachy boost radiotherapy had better oncological outcomes among high-risk patients was the one published by Sathya et al. in 2005. … READ MORE …